Skip to content
October 25–27, 2027 · Orlando

Talk Details · Diabetes 2025

Evaluating the severity of acute pancreatitis in type 2 diabetes patients treated with incretin-based therapies versus insulin: A multicenter retrospective analysis using APACHE II

Oral · In-Person · Day 1

Abstract

About this talk

This multicenter retrospective study investigates whether incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) influence the severity of acute pancreatitis compared to insulin in patients with type 2 diabetes mellitus. Using the APACHE II scoring system as a validated predictor of severity and ICU-level outcomes, we analyzed 192 patient records from three institutions between 2017–2022. Patients were stratified into two cohorts: those on incretin-based therapies and those on basal/bolus insulin therapy. Findings demonstrated no statistically significant difference in APACHE II scores between the two groups; however, patients on incretin-based agents showed a modest trend toward lower ICU admission rates and reduced length of stay. These results suggest that incretin-based therapies are not associated with worse pancreatitis severity and may, in select populations, be a safer long-term glycemic option with pancreatic tolerability. Additional prospective research is warranted to further validate these findings and explore potential protective mechanisms.

Speaker

About the speaker

Anil Harrison

Anil Harrison

Midwestern University, United States

View full speaker profile →

Join the Diabetes 2027 delegation

Orlando · October 25–27, 2027· Hybrid · in-person & virtual

Register as Delegate →

Attend without presenting.